XML 13 R4.htm IDEA: XBRL DOCUMENT v3.22.2
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Revenue:        
Total revenue $ 29,806 $ 24,364 $ 90,633 $ 62,793
Operating costs and expenses:        
Cost of goods sold $ 6,809 $ 3,078 $ 11,048 $ 6,479
Cost, Product and Service [Extensible List] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member] Product Revenue, Net [Member]
Research and development $ 70,963 $ 122,567 $ 159,981 $ 197,243
General and administrative     60,820 63,334
Selling, general and administrative 30,258 32,554    
Total operating costs and expenses 108,030 158,199 231,849 267,056
Loss from operations (78,224) (133,835) (141,216) (204,263)
Interest and other, net        
Interest expense (141) (355) (238) (856)
Interest income and other income (expenses), net 5,199 (363) 4,876 (817)
Total interest and other, net 5,058 (718) 4,638 (1,673)
Loss before income taxes (73,166) (134,553) (136,578) (205,936)
Provision for (benefit from) income taxes 23 (3) 136 130
Investment income in unconsolidated variable interest entity 565 562 885 323
Net loss $ (72,624) $ (133,988) $ (135,829) $ (205,743)
Net loss per share - basic $ (0.78) $ (1.45) $ (1.46) $ (2.24)
Net loss per share - diluted $ (0.78) $ (1.45) $ (1.46) $ (2.24)
Weighted average number of common shares used to calculate net loss per share - basic 93,475 92,276 93,260 91,983
Weighted average number of common shares used to calculate net loss per share - diluted 93,475 92,276 93,260 91,983
License Revenue [Member]        
Revenue:        
Total revenue $ 0 $ 0 $ 22,590 $ 0
Development and Other Revenue [Member]        
Revenue:        
Total revenue 5,457 19,641 17,219 34,228
Product Revenue, Net [Member]        
Revenue:        
Total revenue 23,256 13,371 42,137 28,733
Drug Product Revenue [Member]        
Revenue:        
Total revenue $ 1,093 $ 8,648 $ 8,687 $ (168)